Tesamorelin Mechanism of Action
How Tesamorelin's stabilized GHRH(1-44) structure stimulates pulsatile growth hormone release, and how its stabilization chemistry compares to CJC-1295 and unmodified GHRH.
A Stabilized GHRH Receptor Agonist
Tesamorelin is a synthetic analog of the first 44 amino acids of native growth-hormone-releasing hormone (GHRH), engineered with an added trans-3-hexenoic acid group at the N-terminus. That modification is the core of Tesamorelin's design: unmodified GHRH is degraded within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4), and the N-terminal stabilization protects the molecule from that degradation pathway, extending its functional half-life enough to be useful as a research and clinical compound.
Binding the GHRH Receptor on Pituitary Somatotrophs
Tesamorelin binds the GHRH receptor expressed on somatotroph cells in the anterior pituitary gland, triggering the same downstream signaling cascade as native GHRH: activation of adenylate cyclase, a rise in intracellular cyclic AMP, and pulsatile release of growth hormone (GH) into circulation. Because Tesamorelin acts on the same receptor as the body's own GHRH rather than an entirely separate pathway, the GH release it stimulates preserves the natural pulsatile pattern of GH secretion, in contrast to a constant, non-pulsatile elevation.
Downstream Effects: GH, IGF-1, and Lipid Metabolism
Released GH acts on the liver to stimulate production of insulin-like growth factor 1 (IGF-1), and acts directly on adipose tissue to promote lipolysis (fat breakdown) — an effect that research has found to be particularly pronounced in visceral fat depots relative to subcutaneous fat. That visceral-fat-selective lipolytic effect is the mechanistic basis for Tesamorelin's research use in visceral adiposity models, and for its FDA-approved clinical indication (as Egrifta) in HIV-associated lipodystrophy specifically.
How This Differs From Related Compounds
Tesamorelin, CJC-1295, and Sermorelin all act on the same GHRH receptor, but differ in how they achieve a longer half-life: Tesamorelin uses N-terminal chemical stabilization, CJC-1295 uses "Drug Affinity Complex" technology that binds circulating albumin, and Sermorelin uses no stabilization at all, representing the original unmodified GHRH(1-29) fragment. Ipamorelin, by contrast, acts on an entirely different receptor — the ghrelin receptor (GHSR1a) — rather than the GHRH receptor. See our full four-way GH-axis compound comparison for how all four compounds' mechanisms and trial data compare.
- GHRH receptor agonism research
- Pulsatile growth hormone release studies
- Visceral adiposity and lipid metabolism research
- Comparative GH-axis mechanism studies
Tesamorelin mechanism questions
What receptor does Tesamorelin act on?
Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, the same receptor targeted by native growth-hormone-releasing hormone, triggering pulsatile growth hormone release.
How does Tesamorelin differ mechanistically from CJC-1295?
Both act on the GHRH receptor, but use different stabilization chemistry to extend their half-life: Tesamorelin uses an N-terminal trans-3-hexenoic acid modification, while CJC-1295 uses Drug Affinity Complex technology that binds circulating albumin.
Interested in Tesamorelin?
See pricing and order on the product page, or browse our other GHRH and growth-hormone peptides.